
Securing top scientific and manufacturing talent is critical for Matrix’s growth in a competitive Indian pharma market, and Kumar’s expertise should accelerate hiring efficiency and pipeline development.
Talent acquisition has become a strategic differentiator in the Indian pharmaceutical sector, where firms race to secure skilled scientists, regulatory experts, and manufacturing professionals. Companies like Matrix Pharmacorp are expanding portfolios in APIs, intermediates, and peptide therapeutics, demanding a robust pipeline of specialized talent. By appointing a dedicated head of talent acquisition, Matrix signals a shift from transactional hiring to a more integrated, long‑term workforce planning approach, aligning recruitment with product development timelines and market expansion goals.
Naresh Kumar G’s résumé reads like a masterclass in life‑science recruitment. Starting in 2010, he progressed through roles at HarNeedi, Nefer HR Consulting, Randstad, and Novartis, before spending six years at Dr Reddy’s Laboratories where he rose to talent advisor for R&D, strategy, and commercial functions. This breadth of experience across multinational CROs, biotech firms, and large pharma gives him a nuanced understanding of the talent ecosystems that power drug discovery and manufacturing. His recent stint at CuraTeQ Biologics further sharpened his expertise in biologics hiring, a segment increasingly central to Matrix’s growth plan.
Looking ahead, Kumar’s mandate at Matrix will likely focus on building a talent brand that attracts high‑caliber scientists and operational staff while reducing time‑to‑fill critical roles. By integrating data‑driven sourcing, employer branding, and cross‑functional workforce analytics, he can help Matrix create a talent pool that supports rapid product launches and regulatory compliance. In a market where talent shortages can delay pipelines, his leadership may provide a competitive edge, positioning Matrix as an employer of choice in the fast‑evolving pharma landscape.
Comments
Want to join the conversation?
Loading comments...